Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin

Lowering the blood concentration of low-density lipoprotein (LDL) cholesterol is the primary strategy employed in treating atherosclerotic disorders; however, most commonly prescribed statins prevent cardiovascular events in just 30% to 40% of treated patients. Therefore, additional treatment is req...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2014-05, Vol.9 (5), p.e96929
Hauptverfasser:	Keyamura, Yuka, Nagano, Chifumi, Kohashi, Masayuki, Niimi, Manabu, Nozako, Masanori, Koyama, Takashi, Yasufuku, Reiko, Imaizumi, Ayako, Itabe, Hiroyuki, Yoshikawa, Tomohiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anticholesteremic Agents - pharmacology Antioxidants - pharmacology Arteriosclerosis Atherosclerosis Atherosclerosis - blood Atherosclerosis - chemically induced Atherosclerosis - drug therapy Atorvastatin Atorvastatin Calcium Biology and Life Sciences Biomarkers - blood Blood levels C-Reactive Protein - metabolism Cardiovascular agents Cholesterol Cholesterol - adverse effects Cholesterol - blood Drug Synergism Heptanoic Acids - pharmacology Heptanoic Acids - therapeutic use High density lipoprotein Lesions Lipids Lipoproteins (high density) Lipoproteins (low density) Low density lipoprotein Low density lipoproteins Medicine and Health Sciences Oxidation Oxidation resistance Paraoxonase Patients Pharmaceuticals Probucol Probucol - pharmacology Pyrroles - pharmacology Pyrroles - therapeutic use Rabbits Statins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!